□ 本报记者安莹 近日，东南大学附属中大医院耳鼻咽喉头颈外科传来喜讯，中大医院耳鼻咽喉头颈外科主任陆玲带领团 队首次运用3D外视镜技术成功开展人工耳蜗植入术，术中践行柔手术、微创理念，充分暴露面隐窝、 圆窗膜后，微创在圆窗膜上开放直径0.4毫米的小窗，缓慢稳定植入直径0.3毫米的电极，以求最大程度 保留残余听力，减轻内耳创伤，各项数据监测显示，耳蜗电极工作状态与神经反应状态均正常，术后患 者平稳度过围手术期，无眩晕、面瘫等不适。这一成果标志着中大医院在耳鼻咽喉头颈外科微创手术领 域实现了新的跨越。 人工耳蜗植入作为目前治疗重度、极重度耳聋的有效手段，通过将声音转化为电信号直接刺激听觉神 经，帮助患者恢复听力。但目前我国人工耳蜗植入率不足5%，远低于发达国家水平，亟需提升公众认 知与医疗技术普及。 3D外视镜赋能手术 五旬患者"追声之旅" 此次手术中运用的3D外视镜技术，通过配备的高清三维视野，将手术部位放大数十倍，让医生仿佛置 身"微观世界"，在狭小的耳蜗空间内精准完成电极植入等精细操作，手术精准度与安全性大幅提升。此 外，三维视野还具备教学演示和视频教学功能，为医学知识的传播和人才培养提供了有力支持。 58 ...

据悉，下一步，国家医保局将指导各省份医保局参考《体被系统医疗服务价格项目立项指南（试 行）》，制定全省份统一的价格基准，由具有价格管理权限的统筹地区对照全省份价格基准，上下浮动 确定实际执行的价格水平。 （文章来源：新华社） 例如，将通过注射、贴敷等方式治疗皮损整合为"皮损治疗费（常规）"，并明确每个皮损以9平方厘米 为基础计价，每增加一个皮损逐个递加收费。对于特殊部位治疗难度较大的情况，设立"累及重要器官 或功能部位"等加收项，充分体现技术劳务价值。 "立项指南也充分考虑了对新技术的兼容性。"张凡介绍，立项指南明确，改良进步项目，可采取"现有 项目兼容"方式简化处理，无需申报新增医疗服务价格项目，经向本地区医疗保障部门备案后可按照对 应的项目执行。 新华财经北京6月18日电（记者徐鹏航）体被系统包括皮肤及毛发、指甲等体表组织。从慢性荨麻疹、 特应性皮炎，到雄激素性脱发，再到烧烫伤、创伤后的创面及瘢痕修复，都属于体被系统治疗的范畴。 国家医保局17日发布《体被系统医疗服务价格项目立项指南（试行）》，统一规范价格项目，守护人 体"第一道屏障"。 "体被系统的疾病种类繁多。"参与立项指南制定的北京积水潭医院皮肤性 ...

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号国际企业大厦 A 座 509 单元 邮编：100033 北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 2025 年限制性股票激 励计划调整授予价格事项的 法律意见 京天股字（2025）第 153-3 号 致：北京阳光诺和药物研究股份有限公司 北京市天元律师事务所（以下简称本所）接受北京阳光诺和药物研究股份有 限公司（以下简称公司或阳光诺和）的委托，担任公司 2025 年限制性股票激励 计划（以下简称本激励计划）的专项中国法律顾问并出具法律意见。 本所及经办律师依据《中华人民共和国公司法》 （以下简称《公司法》）、 《中 华人民共和国证券法》 （以下简称《证券法》）、 《律师事务所从事证券法律业务管 理办法》《上市公司股权激励管理办法》（以下简称《管理办法》）、《上海证券交 易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权激励 信息披露》等法律、法规和中国证券监督管理委员会（以下简称中国证监会）的 有关规定及本法律意见出具日以前已经发生或者存在的事实，按照 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 调整公司 2025 年限制性股票激励计划授予价格：22.78 元/股调整为 22.62 元 /股 证券代码：688621 证券简称：阳光诺和 公告编号：2025-055 北京阳光诺和药物研究股份有限公司 关于调整公司 2025 年限制性股票激励计划授予价格 的公告 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"阳光诺和"）于 第六次会议审议通过了《关于调整公司 2025 年限制性股票激励计划授予价格的 议案》等议案。鉴于公司已于 2025 年 6 月 11 日实施完毕 2024 年年度权益分派， 根据《2025 年限制性股票激励计划（草案）》（以下简称"《激励计划（草案）》"） 的规定及公司 2025 年第二次临时股东会的授权，对公司 2025 年限制性股票激励 计划（以下简称"本次激励计划"或"激励计划"）的 2025 年限制性股票激励计划 授予价格进行调整。授予价格（含预留部分）由 22.78 元/股调整为 22.62 元/股。 现将有关事项说 ...

Core Viewpoint - The establishment of the Fudan University Zhongshan Hospital Heart Valve Disease Treatment Center marks a significant advancement in the diagnosis and treatment of heart valve diseases in China, emphasizing a multidisciplinary approach to patient care [1][7][10]. Group 1: Heart Valve Disease Overview - Heart valve disease is a common yet complex cardiovascular condition affecting the heart's valve structures, leading to serious complications such as heart failure and arrhythmias [3][5]. - The prevalence of heart valve disease in China is approximately 3.8%, equating to around 25 million patients, with a notable increase in risk for individuals over 60 years old [5][10]. Group 2: Treatment Innovations - Advances in medical technology have shifted treatment strategies from traditional open surgery to minimally invasive procedures and transcatheter interventions, allowing for earlier intervention in high-risk patients [5][10]. - The Zhongshan Hospital Heart Valve Disease Center integrates various medical disciplines to create a comprehensive treatment model, enhancing the efficiency of care for critically ill patients [7][9]. Group 3: Center's Achievements and Future Plans - Since its establishment, the center has performed nearly 1,000 interventional valve surgeries and over 1,100 minimally invasive surgeries, positioning itself among the international leaders in this field [10]. - The center aims to continue fostering the integration of clinical practice, research, and translational medicine to contribute to the "Healthy China" strategy and improve the management of major cardiovascular diseases [10].

Core Viewpoint - Ping An Health Insurance and U-Health have launched the first one-stop cross-border medical service product in the Greater Bay Area, integrating quality medical resources from mainland China and Hong Kong to provide comprehensive medical assistance services [1][9]. Group 1: Product Launch and Features - The new product "Health Medical +1, Bay Area Home to Home" offers services such as outpatient assistance, expert consultations, rapid accompaniment, transportation assistance to hospitals, and inpatient support [1][10]. - The service aims to provide a seamless experience for clients traveling from home to hospitals and back, addressing the growing demand for cross-border medical services in the Greater Bay Area [9][10]. Group 2: Strategic Collaboration - Ping An Health Insurance's Assistant General Manager Lin Sheng emphasized the company's commitment to the "Healthy Bay Area" initiative, aiming to enhance the connectivity of quality medical resources [3][4]. - U-Health's CEO Zheng Ming'en expressed confidence that the collaboration would create a benchmark for cross-border medical services in the Greater Bay Area, leveraging both companies' strengths [6][9]. Group 3: Market Demand and Service Network - The demand for cross-border medical services has been increasing due to more frequent exchanges in the Greater Bay Area, with challenges such as limited access to quality medical resources and poor patient experience [9]. - Ping An Health Insurance has established a medical network covering 337 cities and 3,045 public tertiary hospitals in China, while U-Health integrates quality private hospital resources in Hong Kong to support efficient medical services [9][10]. Group 4: Customer Engagement and Anniversary Initiatives - In 2025, Ping An Health Insurance will celebrate its 20th anniversary, launching a customer engagement initiative that includes a commitment to immediate claims processing for hospitalized clients and a range of health gifts for customers [11][14]. - The cross-border medical service is part of the company's broader strategy to enhance customer experience and expand its overseas medical health service system [11][14].

Group 1 - The article highlights the economic strength of Jiangsu province, showcasing the competitive dynamics among its 13 cities, referred to as "Thirteen Taibao" [1][25] - Suzhou leads with a GDP of 2.67 trillion yuan in 2024, making it the only city in Jiangsu to surpass 2 trillion yuan, and it is recognized as a national economic powerhouse [2][4] - Suzhou's industrial output is projected to exceed 4.7 trillion yuan in 2024, with a foreign trade volume of 2.62 trillion yuan, indicating its status as a global manufacturing and innovation hub [4][7] Group 2 - Nanjing and Wuxi follow Suzhou, with GDPs of 1.85 trillion yuan and over 1.5 trillion yuan respectively, highlighting their roles as the provincial capital and manufacturing leaders [8][10] - Nanjing's digital economy contributes 16.5% to its GDP, while Wuxi is recognized for its strengths in the Internet of Things and semiconductor industries [10][12] - Emerging cities like Nantong and Changzhou have also joined the trillion-yuan club, driven by their unique industrial strengths [13][14] Group 3 - Suzhou's growth trajectory shows an average annual increase of over 150 billion yuan over the past decade, aiming for a GDP target of 3 trillion yuan by 2026 [7][8] - The article emphasizes the growth potential of northern Jiangsu cities, with Huai'an leading the province with a growth rate of 7.1% [16][18] - Jiangsu's industrial landscape is characterized by "hidden champions," with companies like InnoSilicon and Jiangsu Hengtong leading in their respective fields [20][24] Group 4 - Jiangsu's strategic "1650" industrial layout includes 14 national advanced manufacturing clusters, ensuring all cities are part of the national advanced manufacturing top 100 [27][28] - The province boasts 706 listed companies with a total market value of approximately 7.06 trillion yuan, with Suzhou having the highest number of listed firms [27][28] - The competitive landscape among Jiangsu's cities is portrayed as a collaborative effort to enhance the province's global competitiveness, rather than mere rivalry [28][31]

Group 1 - The core viewpoint of the article emphasizes the high-quality collaborative development between commercial health insurance and the pharmaceutical industry, highlighting the interdependent relationship between medical service providers and insurance payment entities [1] - The historical development of the medical service system and the pharmaceutical industry reveals a complex interplay with insurance payment mechanisms, indicating potential areas for collaboration and growth [1][2] - The transition from a government-subsidized healthcare model to a market-driven approach has led to significant changes in the operational dynamics of public hospitals and the pharmaceutical sector [3][4] Group 2 - The period from 2009 to 2017 marked a significant phase in the reform of public hospital compensation mechanisms, with a focus on balancing the roles of medical service providers and insurance payers [9][10] - The introduction of the "New Medical Reform" in 2009 aimed to establish a public health service system that covers urban and rural residents, although challenges in implementation persisted [9][14] - The commercial health insurance market experienced substantial growth during this period, with premiums increasing tenfold, reflecting a rising demand for supplementary health coverage [6][15] Group 3 - The establishment of the National Healthcare Security Administration in 2018 initiated a new phase of medical reform, introducing diverse payment methods and enhancing regulatory oversight of healthcare expenditures [20][21] - The shift towards a more refined management approach in healthcare institutions is driven by the need to control costs and improve service quality, influenced by changes in insurance payment structures [23][24] - The integration of commercial health insurance with the healthcare system is expected to accelerate, particularly in the high-end medical service sector, as consumer demand for quality healthcare rises [26][27] Group 4 - The pharmaceutical industry in China has undergone significant transformations, with a notable shift towards biopharmaceuticals and innovative drug development, supported by government policies [30][31] - The rapid growth of the Chinese pharmaceutical market has positioned it as the second-largest globally, with a compound annual growth rate of 7.8% from 2010 to 2020 [31][33] - Despite the overall market expansion, challenges such as structural oversupply and the need for higher-quality products remain prevalent, necessitating ongoing industry adjustments [33][34]

Core Insights - The perception of hospitals is shifting from a place for illness treatment to a cost-effective alternative for wellness services, particularly among young workers [2][24] - Community hospitals are becoming popular for affordable services like massage and rehabilitation, often at a fraction of the cost of private clinics [4][10] - Young individuals are increasingly utilizing hospital services for various health and wellness needs, including skincare, nutrition, and eye care, leveraging insurance for cost savings [25][29] Group 1: Community Hospitals and Wellness Services - Community hospitals offer professional massage services at prices as low as 20-30 yuan after insurance reimbursement, significantly cheaper than private massage parlors [7][8] - The efficiency of community hospitals allows patients to receive care without long wait times, enhancing the overall experience compared to larger hospitals [6][9] - The high reimbursement rates for community hospitals, sometimes reaching 85%, make them an attractive option for cost-conscious consumers [7] Group 2: Rehabilitation and Fitness - Rehabilitation departments in hospitals are being redefined as alternatives to traditional gyms, offering personalized fitness guidance at lower costs [10][19] - Patients are finding that rehabilitation services can address a wide range of physical issues, from joint pain to posture correction, often with a more scientific approach than typical fitness programs [12][18] - The experience in rehabilitation departments is described as more supportive and less competitive than traditional gym environments, appealing to those focused on health rather than aesthetics [23] Group 3: Young Consumers and Health Management - Young consumers are actively exploring hospital services for skincare, nutrition, and wellness, viewing them as more reliable and cost-effective than commercial alternatives [25][28] - The trend includes using hospital-developed skincare products, which are often cheaper and perceived as effective as high-end brands [27][26] - There is a growing interest in herbal teas and traditional Chinese medicine as part of a holistic approach to health, with many opting for these over commercial beverages [29][30]

Group 1 - The recent unified examination for data asset accounting and data transaction professionals saw a record number of participants, reflecting the market's urgent demand for specialized talent and the increasing requirements for the standardization and professionalism of data asset accounting by enterprises [1][2] - The implementation of the "Interim Provisions on Accounting Treatment of Enterprise Data Resources" starting January 1, 2024, is driving companies to explore data asset applications, aiming to fully realize the value of data assets [2][3] - Companies are increasingly innovating in data asset applications, as seen in the case of Meinian Health Industry Holdings, which is actively promoting data resource accounting to enhance its capabilities in data management and application [2][3] Group 2 - A shift from initial diverse explorations of data asset accounting to standardized operations is occurring as more companies engage in data asset accounting practices [2][3] - The first disclosures of data asset accounting information by A-share listed companies were simplistic, but recent reports show detailed explanations of amortization methods and a more comprehensive accounting treatment and disclosure system [3] - The growing demand for standardized data asset accounting is leading to an upgrade across the related industry chain, with a new ecosystem for training, examination, and certification of professionals emerging [4][5] Group 3 - Companies are focusing on enhancing data asset quality through technological innovations, as demonstrated by Beijing Sanyuan Gene Pharmaceutical, which has established a comprehensive equipment management system to improve operational efficiency [2][3] - The increasing specialization in data asset accounting is creating a market for related products and services, with many companies positioning themselves to seize market opportunities [4][5] - The standardization and acceleration of data asset evaluation and accounting processes will contribute to a more transparent and trustworthy data market, promoting the adoption of data-driven business models across various industries [6]